Login
  • Home
  • Direct Healthcare Professional Communications

all ( 13 results found)

Sort by:

Date Last Updated:

Medicine Status DHPC Document Name Additional Communications Company Kymriah 1.2 x 106 – 6 x 108 cells dispersion for infusion
Updated

DHPC - Risk of secondary malignancy of T-cell origin in CD19- or BCMA-directed CAR T-cell therapies

COM 18/07/24
Novartis Ireland Limited Dzuveo 30 micrograms sublingual tablet
Updated

Dzuveo cover letter

Dzuveo DHCP letter

COM 14/07/23 COM 14/07/23
Aguettant Ltd Epipen Junior 150 micrograms solution for injection in pre-filled pen
No Recent Update

EpiPen® Healthcare Professional Letter

COM 15/08/23
Mylan IRE Healthcare Ltd Epipen 300 micrograms solution for injection in pre-filled pen
No Recent Update

EpiPen® Healthcare Professional Letter

COM 15/08/23
Mylan IRE Healthcare Ltd Quinsair 240 mg nebuliser solution
No Recent Update

Fluoroquinolones DHPC_HPRA_FINAL vs2 30-05-23

COM 14/06/23
Chiesi Limited Gavreto 100 mg hard capsules
No Recent Update

Gavreto DHPC dated 16 Jun 2023

COM 19/06/23
Roche Registration GmbH Topamax Sprinkle 25 mg hard capsules
Updated

Topiramate: New restrictions to prevent exposure during pregnancy

COM 02/11/23
Janssen Sciences Ireland Topamax Sprinkle 15 mg hard capsules
Updated

Topiramate: New restrictions to prevent exposure during pregnancy

COM 02/11/23
Janssen Sciences Ireland Topamax 50mg film-coated tablets
Updated

Topiramate: New restrictions to prevent exposure during pregnancy

COM 02/11/23
Janssen Sciences Ireland Topamax 25mg film-coated tablet
Updated

Topiramate: New restrictions to prevent exposure during pregnancy

COM 02/11/23
Janssen Sciences Ireland Topamax 200mg film-coated tablets
Updated

Topiramate: New restrictions to prevent exposure during pregnancy

COM 02/11/23
Janssen Sciences Ireland Topamax 100mg film-coated tablets
Updated

Topiramate: New restrictions to prevent exposure during pregnancy

COM 02/11/23
Janssen Sciences Ireland Zolgensma 2 × 1013 vector genomes/mL solution for infusion
No Recent Update

Zolgensma (onasemnogene abeparvovec): Important Safety Information

COM 20/02/23
Novartis Ireland Limited